Potential Benefits of Psilocybin for Lupus Pain: A Case Report.

IF 1.2 Q4 RHEUMATOLOGY
Sofia Audrey B Gonzales, Christine Alexopoulos, Daniel G Arkfeld
{"title":"Potential Benefits of Psilocybin for Lupus Pain: A Case Report.","authors":"Sofia Audrey B Gonzales, Christine Alexopoulos, Daniel G Arkfeld","doi":"10.2174/1573397119666230904150750","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Outcomes of treatment for patients with Lupus have shown overall improvement and benefit from the more aggressive use of immunosuppressants and biological agents through a treat-to-target approach. However, chronic musculoskeletal pain can be refractory to treatment despite the use of non-steroidal anti-inflammatory drugs, corticosteroids, and other analgesic agents, leading to patient dissatisfaction. The concept of new neural pathways from psilocybin usage has been proposed in a variety of pain syndromes; however, it is not trialed for patients with Lupus pain.</p><p><strong>Case presentation: </strong>The patient was a 67-year-old male with positive anti-dsDNA antibody Lupus with a predominance of chronic polyarticular joint pain treated with hydroxychloroquine and non-steroidal anti-inflammatory drugs without pain relief. Pain dramatically improved after a one-time macro-dosing of 6 grams of Psilocybin cubensis in Oregon, which he expected would only provide a sense of enlightenment. After 12 months, he continued without debilitating joint pain.</p><p><strong>Conclusion: </strong>The serotonin-2A receptor's activation triggers an array of neurophysiological reactions that disrupt the functional connections in areas of the brain that are associated with chronic pain. These neuroplastic effects can generate healthy connections, resulting in long-lasting pain relief. However, this is a process that has not been fully analyzed. While there is anecdotal evidence to suggest the therapeutic benefits for autoimmune diseases, including rheumatoid arthritis and psoriasis, there is no specific research that explores its use for lupus-related pain. Since this is the first case that shows the benefit of psilocybin in a patient with Lupus, further studies on macro-dosing psilocybin to treat Lupus pain are warranted.</p>","PeriodicalId":11188,"journal":{"name":"Current rheumatology reviews","volume":" ","pages":"97-99"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current rheumatology reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573397119666230904150750","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Outcomes of treatment for patients with Lupus have shown overall improvement and benefit from the more aggressive use of immunosuppressants and biological agents through a treat-to-target approach. However, chronic musculoskeletal pain can be refractory to treatment despite the use of non-steroidal anti-inflammatory drugs, corticosteroids, and other analgesic agents, leading to patient dissatisfaction. The concept of new neural pathways from psilocybin usage has been proposed in a variety of pain syndromes; however, it is not trialed for patients with Lupus pain.

Case presentation: The patient was a 67-year-old male with positive anti-dsDNA antibody Lupus with a predominance of chronic polyarticular joint pain treated with hydroxychloroquine and non-steroidal anti-inflammatory drugs without pain relief. Pain dramatically improved after a one-time macro-dosing of 6 grams of Psilocybin cubensis in Oregon, which he expected would only provide a sense of enlightenment. After 12 months, he continued without debilitating joint pain.

Conclusion: The serotonin-2A receptor's activation triggers an array of neurophysiological reactions that disrupt the functional connections in areas of the brain that are associated with chronic pain. These neuroplastic effects can generate healthy connections, resulting in long-lasting pain relief. However, this is a process that has not been fully analyzed. While there is anecdotal evidence to suggest the therapeutic benefits for autoimmune diseases, including rheumatoid arthritis and psoriasis, there is no specific research that explores its use for lupus-related pain. Since this is the first case that shows the benefit of psilocybin in a patient with Lupus, further studies on macro-dosing psilocybin to treat Lupus pain are warranted.

迷幻药对红斑狼疮疼痛的潜在益处:一份病例报告。
导言:红斑狼疮患者的治疗结果表明,通过靶向治疗的方法更积极地使用免疫抑制剂和生物制剂,患者的总体病情得到了改善,并从中获益。然而,尽管使用了非甾体抗炎药、皮质类固醇和其他镇痛剂,慢性肌肉骨骼疼痛仍可能难治,导致患者不满。在多种疼痛综合征中使用迷幻药会产生新的神经通路,这一概念已被提出;但是,狼疮疼痛患者尚未试用过迷幻药:患者是一名 67 岁的男性,抗 DNA 抗体阳性,患有以慢性多关节痛为主的红斑狼疮,曾使用羟氯喹和非甾体抗炎药治疗,但疼痛并未缓解。他在俄勒冈州一次性大量服用了 6 克西洛西宾(Psilocybin cubensis)后,疼痛明显好转,他认为这只会给他带来一种启迪。12 个月后,他的关节不再疼痛难忍:5-羟色胺-2A 受体的激活会引发一系列神经生理反应,破坏与慢性疼痛相关的大脑区域的功能连接。这些神经可塑性效应可以产生健康的连接,从而带来持久的疼痛缓解。然而,这一过程尚未得到充分分析。虽然有轶事证据表明,这种疗法对包括类风湿性关节炎和牛皮癣在内的自身免疫性疾病有治疗效果,但目前还没有具体的研究来探讨它对红斑狼疮相关疼痛的治疗效果。由于这是第一个显示迷幻药对红斑狼疮患者有益的病例,因此有必要对大剂量迷幻药治疗红斑狼疮疼痛进行进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
82
期刊介绍: Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in rheumatology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信